Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy

• Status: Unknown status
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Recent studies have established the reliability, validity and time course of the cannabis withdrawal syndrome. This study will investigate the effects of combined treatment of Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the marijuana withdrawal syndrome in regular chronic users of marijuana. We predict that combined pharmacological treatment and cognitive-behavior therapy will help patients to abstain from using using marijuana and it will alleviate their marijuana withdrawal symptoms.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tel-Aviv Sourasky Medical Center
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Men and women aged 20-45

• DSM IV criteria of marijuana dependence.

Exclusion Criteria:

• Other drug or alcohol dependence

• Bipolar disorder, schizophrenia, major depression, suicidal ideation, psychotic symptoms or violent thoughts

• Physical illness including hypothyroidism, neurological disease, severe anemia, and renal failure

• Past severe side effects of SSRIs.